Moderna says the RSV vaccine is 84% ​​effective at preventing the disease in older adults

MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE

A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination center in Antwerp, Belgium, on February 1, 2022.

Johanna Geron | Reuters

Moderna said Tuesday that its vaccine against respiratory syncytial virus is effective in preventing the disease in older adults.

The vaccine was 83.7 percent effective in preventing lower respiratory tract disease, defined as two or more symptoms, in people age 60 and older, according to the Boston-based biotech company. It was 82.4 percent effective in preventing lower respiratory tract disease with three or more symptoms.

Moderna said it plans to file for approval with the Food and Drug Administration in the first half of this year. There is currently no FDA-approved RSV vaccine.

RSV infections kill between 6,000 and 10,000 older adults and cause 60,000 to 120,000 hospitalizations each year, according to the Centers for Disease Control and Prevention.

The US suffered an unusually severe RSV season among children and older adults last fall as the public largely stopped practicing public health measures implemented in response to the Covid-19 pandemic, such as masking and social distancing.

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid vaccines. The Covid vaccine turned Moderna into a global name and brought in windfall profits, but it remains the company’s only commercially available product and demand is waning.

The Boston biotech company is facing increasing pressure to prove that other products in its pipeline will make it to market. Morgan Stanley estimates the market for the RSV vaccine for adults at $7 billion to $10 billion.

CNBC Health & Science

Read CNBC’s latest global health coverage:

.

MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE

Source

Leave a Comment

error: Content is protected !!